MedTrace Logo

Use of Ritual Epost Postnatal Multivitamins During the Postpartum Period

NCT05736562 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 71

Last updated 2026-05-19

No results posted yet for this study

Summary

Multivitamin/multimineral supplements (MVI) provide important nutrition supplement to the diet of pregnant women to cover potential deficiencies and optimize nutrition status of both mom and baby, especially when the diet is suboptimal or nutrient demand is high while absorption is hindered by various factors such as genetic variance and gastrointestinal function. It is, however, largely unknown whether using an MVI during the lactating period helps improve nutrition status of mom and baby. In this double-blind, randomized, controlled trial, the investigators will recruit 7- postpartum women who exclusively breastfeed at week 5 postpartum and randomly assign them to either receive the Ritual MVI which is commercially available or a blank placebo for 10 weeks. A blank placebo is appropriate because there is currently no recommendation or scientific consensus that lactating women who are healthy and eat a normal diet would have improved nutrition status or maternal-infant health outcomes from a nutrition supplement. The investigators will collect blood and breastmilk samples at baseline and end of the study to assess nutrient status. The investigators hypothesize that consumption of a Ritual MVI leads to better nutrition status and biomarkers in maternal-child dyads compared to control.

Conditions

  • Lactation Disorder - Postpartum Condition or Complication
  • Nutrition, Healthy

Interventions

DIETARY_SUPPLEMENT

Ritual Epre Multimineral-Vitamin Supplement

The Ritual Epre supplement is a commercially available multivitamin-mineral supplement designed for pregnant and lactating women.

DIETARY_SUPPLEMENT

Placebo Control

This is a customarily designed blank placebo provided by Ritual.

Sponsors & Collaborators

  • Maimonides Medical Center

    collaborator OTHER

  • City University of New York

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2023-10-15
Primary Completion
2025-09-30
Completion
2026-05-15

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05736562 on ClinicalTrials.gov